MAIN ARTICLE
A wellness trend becomes a commercial offering
Peptides are short chains of amino acids. Some have well-established medical applications when studied and approved for specific indications, but that does not validate every substance promoted by wellness influencers. Hims & Hers expects to launch glutathione, sermorelin and NAD+ in November, with BPC-157 and TB-500 planned later. NAD+ is a coenzyme involved in cellular metabolism, rather than a peptide—a useful distinction when several scientifically different substances are presented together as part of a wellness portfolio.
The market's appeal reflects interest in recovery, healthy aging and convenient access to treatment online. Popularity, however, does not substitute for controlled clinical trials. Claims about improved athletic performance, rejuvenation or tissue healing require evidence specific to the substance, formulation and route of administration; personal testimonials cannot establish either effectiveness or safety.
Regulatory flexibility is not FDA approval
Reuters reported that the US government eased restrictions surrounding the compounding of certain unapproved substances. Such an adjustment reflects enforcement policy, not a finding that the FDA has verified a treatment's safety or effectiveness.














